Oral peptide delivery: Prioritizing the leading technologies

Therapeutic Delivery

Volumn 2, Issue 12, 2011, Pages 1567-1573

  Brayden, David J ^a   Mrsny, Randall J ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b University of Bath   (United Kingdom)

Author keywords

Absorption promoters; Intestinal epithelial permeability; Oral excipients; Oral macromolecule delivery; Oral peptides

Indexed keywords

EXCIPIENT; INSULIN; IONIC SURFACTANT; MACROGOL; MEMBRANE RECEPTOR; NANOPARTICLE; NONIONIC SURFACTANT;

APICAL MEMBRANE; DIABETES MELLITUS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; NOTE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

EID: 81255156967     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.114     Document Type: Note

References (36)

1. Walsh E, Maher S, Adamczyk B et al. Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET®). Therapeutic Delivery 2(12), 1595-1610 (2011).
2. Aungst BJ. Absorption enhancers: applications and advances. AAPS J. (2011) (In Press).
3. Aungst BJ. Intestinal permeation enhancers. J. Pharm. Sci. 89, 429-442 (2000).
4. Maher S, Leonard TW, Jacobsen J, Brayden DJ. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61, 1427-1449 (2009).
5. Sinko PJ, Lee YH, Makhey V et al. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm. Res. 16, 527-533 (1999). (Pubitemid 29191297)
6. Riley MG, Castelli MC, Paehler EA. Sub-chronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats. Int. J. Toxicol. 28(4), 278-293 (2009).
7. Fasano A, Uzzau S. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest. 99, 1158-1164 (1997). (Pubitemid 27142750)
8. Goldblum SE, Rai U, Tripathi A et al. The active Zot domain (aa 288-293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation. FASEB J. 25, 144-1458 (2011).
9. Takahashi A, Kondoh M, Uchida H, Kakamu Y, Hamakubo T, Yagi K. Mutated C-terminal fragments of Clostridium perfringens enterotoxin have increased affinity to claudin-4 and reversibly modulate tight junctions in vitro. Biochem. Biophys. Res. Commun. 410, 466-470 (2011).
10. Maher S, Wang X, Bzik V, McClean S, Brayden DJ. Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies. Eur. J. Pharm. Sci. 38(4), 301-311 (2009).
11. Tavelin S, Hashimoto K, Malkinson J, Lazorova L, Toth I, Artursson P. A new principle for tight junction modulation based on occludin peptides. Mol. Pharmacol. 64, 1530-1540 (2003). (Pubitemid 37532242)
12. Mrsny RJ, Brown GT, Gerner-Smidt K et al. A key claudin extracellular loop domain is critical for epithelial barrier integrity. Am. J. Pathol. 172, 905-915 (2008). (Pubitemid 351519988)
13. Swenson ES, Milisen WB, Curatolo W. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm. Res. 11, 1132-1142 (1994). (Pubitemid 24259853)
14. Wang X, Maher S, Brayden DJ. Restoration of rat colonic epithelium after in situ intestinal instillation of the absorption promoter, sodium caprate. Therapeutic Delivery 1, 65-72 (2010).
15. Baluom M, Friedman M, Assaf P, Haj-Yehia AI, Rubinstein A. Synchronized release of sulpiride and sodium decanoate from HPMC matrices: a rational approach to enhance sulpiride absorption in the rat intestine. Pharm. Res. 17, 1071-1076 (2000).
16. 12 mediated oral delivery systems for granulocyte-colony stimulating factor and erythropoietin. Bioconjug. Chem. 6, 459-465 (1995)
17. Coyne CB, Kelly MM, Boucher RC, Johnson LG. Enhanced epithelial gene transfer by modulation of tight junctions with sodium caprate. Am. J. Respir. Cell Mol. Biol. 23, 602-609 (2000).
18. Cox AB, Rawlinson L, Baird AW, Bzik V, Brayden DJ. In vitro interactions between the oral absorption promoter, sodium caprate (C10) and S. typhimurium in rat intestinal ileal mucosae. Pharm. Res. 25, 114-122 (2008).
19. Okada J, Cohen S, Langer R. In vitro evaluation of polymerized liposomes as an oral drug delivery system. Pharm. Res. 12, 576-582 (1995).
20. Clark A, Blair H, Liang L, Brey R, Brayden DJ, Hirst B. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20, 208-217 (2001). (Pubitemid 32905334)
21. Prego C, García M, Torres D, Alonso MJ. Transmucosal macromolecular drug delivery. J. Control. Release 10, 151-162 (2005). (Pubitemid 39600979)
22. Slütter B, Bal S, Keijzer C et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 28, 6282-6291 (2010).
23. Katz DE, DeLorimier AJ, Wolf MK et al. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 21, 341-346 (2003). (Pubitemid 36091922)
24. Garinot M, Fiévez V, Pourcelle V et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release 120, 195-204 (2007). (Pubitemid 47061488)
25. Furtado S, Abramson D, Burrill R et al. Oral delivery of insulin loaded poly(fumaric-co-sebacic) anhydride microspheres. Int. J. Pharm. 347, 149-155 (2008). (Pubitemid 350180326)
26. Goldberg DS, Vijayalakshmi N, Swaan PW, Ghandehari H. G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. J. Control. Release 150, 318-325 (2011).
27. Thompson C, Cheng WP, Gadad P et al. Uptake and transport of novel amphiphilic polyelectrolyte-insulin nanocomplexes by Caco-2 cells-towards oral insulin. Pharm. Res. 28, 886-896 (2011).
28. Vrignaud S, Benoit JP, Saulnier P. Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles. Biomaterials 32(33), 8593-8604 (2011).
29. Tang BC, Dawson M, Lai SK et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl Acad. Sci. USA 106, 19268-19273 (2009).
30. Fievez V, Plapied L, Plaideau C et al. In vitro identification of targeting ligands of human M cells by phage display. Int. J. Pharm. 394, 35-42 (2010).
31. Lim CJ, Shen WC. Comparison of monomeric and oligomeric transferrin as potential carrier in oral delivery of protein drugs. J. Control. Release 106, 273-286 (2005).
32. Bitonti AJ, Dumont JA, Low SC et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl Acad. Sci. USA 101, 9763-9768 (2004). (Pubitemid 38869310)
33. 12 bioconjugate pharmaceutical. Expert Opin. Drug Deliv. 8, 127-140 (2011).
34. Hazra P, Adhikary L, Dave N et al. Development of a process to manufacture PEGylated orally bioavailable insulin. Biotechnol. Prog. 26, 1695-1704 (2010).
35. Iyer H, Khedkar A, Verma M. Oral insulin -a review of current status. Diabetes Obes. Metab. 12, 179-185 (2010).
36. Youn YS, Jung JY, Oh SH, Yoo SD, Lee KC. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J. Control. Release 114, 334-342 (2006). (Pubitemid 44310815)